Last updated: June 25, 2026
Takeda Pharmaceutical Company Ltd. v. Torrent Pharmaceuticals Ltd. (D.N.J., No. 2:17-cv-03186) is a Hatch-Waxman patent infringement suit tied to an FDA abbreviated-approval (ANDA) by Torrent and associated Orange Book-listed patents asserted by Takeda. The case posture and the specific asserted patents, the exact drug product, and the claim construction record are not provided in the input, so a complete, accurate litigation summary (patents-in-suit, asserted claims, key rulings, settlement terms, and generic launch timeline impact) cannot be produced.
What is the case timeline for Takeda v. Torrent 2:17-cv-03186?
Answer: Insufficient information in the provided prompt to reconstruct an accurate timeline of filings, amendments, claim-scope events, Markman, dispositive rulings, trial status, and any settlement or dismissal dates.
Docket milestones that must be verified from the record
- Complaint filing date and jurisdictional basis
- Service and answer deadlines
- Patent list and asserted counts (counts by patent and claim)
- Scheduling order entries (Markman, summary judgment, pretrial, trial)
- PTAB activity (if any) affecting litigation stay or estoppel
- Final judgment and any appeal entries
Which patents did Takeda assert against Torrent in 2:17-cv-03186?
Answer: Not specified in the provided prompt. Without the Orange Book/patent list and the complaint caption content, the asserted patents and their numbers cannot be stated accurately.
What “patents-in-suit” analysis normally includes
- Orange Book publication identifiers and patent numbers
- Patent type breakdown:
- Composition of matter
- Method of use
- Formulation/composition-specific patents
- Manufacturing/process patents
- Claim-to-product mapping:
- Drug substance vs. drug product
- Dosage form and strength coverage
- Indications tied to method-of-use claims
What is the litigation posture in Takeda v. Torrent 2:17-cv-03186 (motions, Markman, summary judgment)?
Answer: Not determinable from the provided prompt. A reliable posture summary requires the docket’s motion history and court orders.
Court steps that typically drive claim scope
- Markman order (construction of key terms)
- Summary judgment on infringement or invalidity defenses
- Evidentiary rulings (expert admissibility)
- Obviousness/anticipation legal standards applied to asserted claims
- Written opinion that narrows or preserves asserted claim sets
How do the infringement and invalidity arguments usually split in these Takeda v. Torrent cases?
Answer: The prompt does not state which defenses were raised or what the parties’ theory was (product equivalence, non-infringement carve-outs, obviousness, enablement, written description, indefiniteness, prosecution history estoppel, or inequitable conduct).
Typical categories that require record-specific verification
- Non-infringement:
- Design-around via formulation or parameter changes
- Claim limitations not met (method steps, concentration ranges, excipients, particle attributes)
- Invalidity:
- Prior art anticipation or obviousness (single reference vs combination)
- Lack of written description/enablement
- Indefiniteness under §112
- Statutory/terminal disclaimers and priority disputes
- Inequitable conduct allegations (materiality and intent)
What Paragraph IV or FDA Orange Book triggers the case 2:17-cv-03186?
Answer: The prompt does not identify:
- The FDA application number (ANDA/BLA)
- The drug name and strength(s)
- The Orange Book patent(s) that supported the Paragraph IV notice(s)
- Whether the case is tied to a Paragraph IV certification and the specific certification type (I-IV)
What must be reported for a true Orange Book exposure analysis
- NDA/ANDA reference listed drug (RLD)
- Listing(s): patent number, expiration, and dosage form
- Torrent’s ANDA certification(s)
- Takeda’s infringement counts tied to each listing
- Statutory 30-month stay status and any carve-outs
Does Takeda v. Torrent 2:17-cv-03186 include a settlement, consent judgment, or dismissal?
Answer: Not stated in the prompt. A settlement/consent-docket analysis requires order dates and terms (earliest generic entry, carve-out products, royalties, covenant not to sue, stipulations).
Settlement terms that drive business exposure
- Entry date and exclusivity window effect
- Scope limitations (strengths, dosage forms, indications)
- License grant terms (if any)
- Forfeiture provisions or triggering events
- Staged launch permission contingent on design-arounds
What generic entry risks exist for Torrent after 2:17-cv-03186?
Answer: The risk cannot be quantified without:
- The final disposition (judgment vs settlement)
- Whether any patents were held invalid, non-infringed, or withdrawn
- Whether there are remaining unasserted Orange Book listings
- Any subsequent FDA approval dates and exclusivity expirations
Risk matrix that must be evidence-based
- If Takeda won:
- Remaining injunction exposure and redesign requirements
- Continued 30-month stay or permanent injunction risk
- If Torrent won or settled:
- Launch date and remaining patent obstacles
- Potential re-litigation on additional patents or continuations
How does this litigation affect FDA approval timing and exclusivity dates?
Answer: Not computable from the provided prompt because the record lacks:
- The reference product and its regulatory exclusivities (marketing exclusivity, pediatric exclusivity, 180-day exclusivity, orphan exclusivity if applicable)
- The ANDA submission date, first-filer status, and 180-day exclusivity forfeiture rules
- Statutory stay start and end dates tied to the Paragraph IV notice
How strong is Takeda’s patent estate relative to Torrent’s ANDA in this case?
Answer: Not possible without the patents-in-suit and the court’s validity/infringement outcomes.
What “strength” analysis requires
- Claim survives construction and summary judgment
- Court’s finding on anticipation/obviousness
- Remaining independent claims after invalidity rulings
- Whether Torrent’s design-around was found to avoid key limitations
Key Takeaways
- The docket identifier (2:17-cv-03186) is insufficient to produce a complete, accurate litigation summary.
- A record-based analysis requires the complaint’s asserted patents, Torrent’s ANDA particulars, and the court’s orders (motion outcomes, claim construction, and final judgment/settlement).
- No defensible statements about timelines, patents-in-suit, or generic entry impacts can be made from the provided input alone.
FAQs
- What patents-in-suit are listed in Takeda’s complaint for 2:17-cv-03186?
- Did the court issue a Markman order in 2:17-cv-03186, and what terms were construed?
- What is the final disposition of Takeda v. Torrent 2:17-cv-03186 (judgment vs settlement)?
- Which Orange Book-listed patents and certification(s) triggered Torrent’s Paragraph IV dispute?
- How did the case affect Torrent’s ability to obtain FDA approval and launch at-risk?
References
(0 items)
